ERBB2 and breast cancer: Amplification of MET may also be important in other molecular subtypes of breast cancer: in a study of 130 Her2-positive breast cancers, both MET and HGF amplification were associated with trastuzumab failure and patients with MET amplified tumours had a shorter time to progression [34].